Skip to content


You're viewing the new version of our site. Please leave us feedback.

Learn more
Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

What is the future of targeted therapy in rheumatology: biologics or small molecules?

  • Attila Mócsai1, 2Email author,
  • László Kovács3 and
  • Péter Gergely4
Contributed equally
BMC Medicine201412:43

Received: 14 November 2013

Accepted: 19 February 2014

Published: 13 March 2014

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting

Original Submission
14 Nov 2013 Submitted Original manuscript
27 Nov 2013 Reviewed Reviewer Report - Steffen Gay
22 Jan 2014 Reviewed Reviewer Report - rieke alten
19 Feb 2014 Author responded Author comments - Alessandro Recchioni
Resubmission - Version 2
19 Feb 2014 Submitted Manuscript version 2
19 Feb 2014 Editorially accepted
13 Mar 2014 Article published 10.1186/1741-7015-12-43

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

Department of Physiology, Semmelweis University School of Medicine
MTA-SE “Lendület” Inflammation Physiology Research Group of the Hungarian Academy of Sciences and the Semmelweis University
Department of Rheumatology, University of Szeged Faculty of Medicine
Translational Medicine Autoimmunity, Novartis Institutes for Biomedical Research